SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL,Gastroenterology

当前位置： X-MOL 学术 › Gastroenterology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
Gastroenterology ( IF 25.7 ) Pub Date : 2024-06-05 , DOI: 10.1016/s0016-5085(24)05018-2
Naim Alkhouri , Mandy Fraessdorf , Guy Neff , Joern M. Schattenberg , Mazen Noureddin , Eric Lawitz , Ǫuentin M. Anstee , Elisabetta Bugianesi , Samina Ajaz Hussain , Philip Newsome , Vlad Ratziu , Azadeh Hosseini-Tabatabaei , Arun J. Sanyal , Ramy Younes

中文翻译：